NEW!

Meeting Schedule
1:00 p.m.–3:00 p.m.
S30 Movement Disorders: Ataxias and Other
Hyperkinetic Movement Disorders
S31 Stroke Risk, Outcomes, and Complications
S32 Neuroepidemiology
S33 Section Topic Controversies: Autoimmune/
Paraneoplastic Neurological Disorders: Update
on Imaging and Antibody Testing
Real World
of NeurologyAsk the Expert: PQRS
C137 Introduction to Primary Headache Disorders I
Director: Todd D. Rozen, MD, FAAN, Jacksonville, FL
C138 Neurologic Intensive Care II
Director: Alejandro A. Rabinstein, MD, FAAN, Rochester, MN
C139 Neuro-ophthalmology II
Director: Nancy J. Newman, MD, FAAN, Atlanta, GA
C140 Clinical Neurology for Advanced Practice
Providers I
Director: Cynthia L. Comella, MD, FAAN, Chicago, IL
C141 Continuum ® Test Your Knowledge: A Multiplechoice
Question Review I
(registration required)
Director: Aaron E. Miller, MD, FAAN, New York, NY
C142 Improving Accuracy of Dementia Diagnosis: Case
Studies with Both Imaging and Neuropathology
Director: Edward Y. Zamrini, MD, Sun City, AZ
C143 Small Fiber Neuropathies: Sensory, Autonomic
and Both I
Director: Christopher H. Gibbons, MD, FAAN, Boston, MA
C144 Multiple Sclerosis Therapy: Symptom
Management
Director: Jonathan L. Carter, MD, Scottsdale, AZ
C145 Circadian Rhythm Disorders
Director: Phyllis C. Zee, MD, PhD, Chicago, IL
C146 Neuroimaging for the General Neurologist: Brain I
Director: Laszlo Mechtler, MD, FAAN, Amherst, NY
C147 $ Clinical Usefulness of Botulinum Toxin for
Spasticity Skills Workshop
(registration required)
Director: Allison Brashear, MD, MBA, FAAN,
Winston Salem, NC
C148 Precision Neurology: The Promise and Perils
of Whole Exome Sequencing for Neurological
Disorders
Director: Amy R. Brooks-Kayal, MD, Aurora, CO
C149 Sports Neurology: Non-concussion Overview I
Director: Brian W. Hainline, MD, FAAN, Indianapolis, IN
C150 Recent History: Shapers of Modern Neurology I
Director: Stephen G. Reich, MD, FAAN, Baltimore, MD
Invited Science:
Movement
Disorders
Tuesday, April 19, 3:30 p.m. to 5:30 p.m.
Top abstracts previously presented at the International
Parkinson and Movement Disorder Society will be
presented by their authors in 20-minute platform
sessions. Select abstracts from their “best of” lineups
emphasize basic, clinical, and translational sciences as
they evolve toward a more complete understanding of
Movement Disorders with the overall goal of developing
more effective prevention and treatment.
3:30 p.m. to 3:50 p.m.
Microglial Dysfunction Plays a Critical Role in
Huntington’s Disease Pathogenesis
Blair Leavitt, MD, Vancouver, BC, Canada
3:50 p.m. to 4:10 p.m.
PREDICT-PD: Identifying Risk of Parkinson’s
Disease in the Community
Alastair John Noyce, MBBS, London, United
Kingdom
4:10 p.m. to 4:30 p.m.
Glucocerebrosidase Activity in Parkinson’s
Disease With and Without GBA Mutations
Roy Alcalay, MD, New York, NY
4:30 p.m. to 4:50 p.m.
Tau-PET Imaging in Progressive Supranuclear
Palsy Using [18F] AV-1451
Daniel Schonhaut, San Francisco, CA
4:50 p.m. to 5:10 p.m.
Inhaled Levodopa (CVT-301) Provides Rapid
Improvement of OFF States in Parkinson’s
Disease
Peter A. LeWitt, MD, West Bloomfield, MI
5:10 p.m. to 5:30 p.m.
Stable Levodopa Plasma Levels With ND0612
(Levodopa/Carbidopa for Subcutaneous
Infusion) in Parkinson’s Disease (PD) Patients
With Motor Fluctuations
Sheila Oren, MD, MBA, Rehovet, Israel
Tue· April 19
Fast and easy registration · AAN.com/view/AM16 103